Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Allogene Therapeutics Inc

ALLO
Current price
2.47 USD -0.17 USD (-6.44%)
Last closed 2.56 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 424 058 016 USD
Yield for 12 month -71.80 %
Week
Month
Year
ALLO
21.11.2021 - 28.11.2021

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 210 East Grand Avenue, South San Francisco, CA, United States, 94080

Analytics

WallStreet Target Price

13.92 USD

P/E ratio

Dividend Yield

Current Year

+243 000 USD

Last Year

+38 489 000 USD

Current Quarter

+43 000 USD

Last Quarter

+44 000 USD

Current Year

+243 000 USD

Last Year

+38 489 000 USD

Current Quarter

+43 000 USD

Last Quarter

+44 000 USD

Key Figures ALLO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -325 147 008 USD
Operating Margin TTM -146453.48 %
PE Ratio
Return On Assets TTM -26.48 %
PEG Ratio
Return On Equity TTM -50.32 %
Wall Street Target Price 13.92 USD
Revenue TTM 186 000 USD
Book Value 3.47 USD
Revenue Per Share TTM 0.001 USD
Dividend Share
Quarterly Revenue Growth YOY -12.2 %
Dividend Yield
Gross Profit TTM 243 000 USD
Earnings Share -2.2 USD
Diluted Eps TTM -2.2 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ALLO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ALLO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ALLO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 261.5817
Price Sales TTM 2279.8818
Enterprise Value EBITDA -0.1496
Price Book MRQ 0.7272

Financials ALLO

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ALLO

For 52 weeks

2.23 USD 9.6 USD
50 Day MA 2.93 USD
Shares Short Prior Month 34 031 762
200 Day MA 4.58 USD
Short Ratio 16.99
Shares Short 32 343 375
Short Percent 28.3 %